Neurocrine Biosciences, Inc. Q3 2025 Earnings Recap

Neurocrine Biosciences showcased robust performance in Q3 2025 with net product sales reaching $790 million, driven by strong growth in both INGREZZA and CRENESSITY as the company executes on its strategic initiatives.

Key Takeaways

• Net sales increased 28% year-over-year, with INGREZZA contributing $687 million and CRENESSITY generating $98 million in its early launch phase.
• Continued investments in expanding the sales force are aligned with projections for significant growth in the tardive dyskinesia market through 2029.
• The company remains on track for its R&D productivity goals, with advancements in multiple Phase I and Phase II studies within its pipeline.
• A planned $150 million increase in SG&A expenses for 2026 reflects a commitment to driving growth in both INGREZZA and CRENESSITY.
• Neurocrine's financial position remains strong with over $2.1 billion in cash, underpinning future investments in innovation and shareholder returns.